Age Related Macular Degeneration Market 2018-2023 With Top Players Bausch & Lomb, Regeneron Pharma, Allergan and Bayer

The global age-related macular degeneration (AMD) is projected to register a better than average CAGR of 8.3% during the forecast period of 2018 to 2023. The AMD market valued 1.37 Bn at the end of 2017 and is expected to reach an approximate evaluation of 2.21 Bn by the end of 2023. The rising prevalence of age-related macular degeneration and the expiry of several drug patents are important contributors to growth for the global AMD market.

As the name of the condition suggests, AMD is age-related and has a high rate of incidence in geriatric patients. According to the 2017 study published in the Clinical Interventions in Aging Journal, AMD is a prominent cause of central visual loss which affects nearly 10% of people over 65 years and over 25% of people over the age of 75 years. Additionally, it has been reported that in the U.S approximately 2 million individuals suffer from advanced AMD and over 8 million individuals suffer from an intermediate form of the disease. The ever-increasing geriatric population has further contributed to the growth of the market and is expected to be a key driver during the forecast period. Another significant driver for the AMD market, is the expiry of drug patents for several popular branded drugs such as Avastin, Macugen, Lucentis, Eylea, and others, thus allowing other manufacturers to improve the efficacy of existing formulas. Expired drug patents additionally allow for a reduction in price points which will make treatment of AMD more affordable.

Currently, the preferred route of treatment for AMD is the use of anti-vascular endothelial growth factor agents (anti-VEGF) with demonstrated efficacy in improving visual acuity. Although various anti-VEGF drugs are available, only a few are used commonly; these include Lucentis (ranibizumab), Eylea (aflibercept). The price of these drug treatments poses a challenge to market growth as the price ranges roughly between USD 1800 to 2000. Moreover, insurance coverage for these drugs in complex and reimbursement policies are unfavorable. Despite these restraints, several clinical trials are underway to efficiently treat dry AMD which is the more common form of the disease. The development of new drugs and the increased efficacy of existing drug formulas by leading market players are expected to reveal opportunities for expansion of the market during the assessment period.

Get Sample Report here https://www.marketresearchfuture.com/sample_request/5736

Age-related Macular Degeneration (AMD) Market – Top Players

• Regeneron Pharmaceutical Inc.
• Novartis AG
• F.Hoffmann-La Roche AG
• Santen Pharmaceuticals
• Bayer AG.
• Pfizer Inc.
• Allergan
• Bausch & Lomb Incorporated
• Rxi Pharmaceuticals
• Alimera Sciences

Global Age-related Macular Degeneration (AMD) Market – Regional Analysis

The Americas, led by the U.S, account for the most significant region across the globe. According to the report published by Centers for Disease Control and Prevention (CDC) in 2015, it was estimated that about 1.8 million people are suffering from age-related macular degenerations in America. Similarly, according to the United States Census Bureau, around 49.2 million adults aged 65 and above were present in the U.S. as of 2016. Growing government initiatives and favorable policies regarding eye-care are expected to propel the region during the forecast period.

Europe, which closely follows the Americas is the second largest market due to the presence of a large geriatric population and increasing incidences of the disease. Government initiatives and an ever-improving healthcare framework combined with the demand for advanced and effective treatment drives the growth of the AMD market in the region. For instance, the Eurostat estimated that over 19.2% of the population in Europe were aged 65 and above in 2016. The presence of prominent players and their research activities are expected to facilitate further growth during the assessment period.

The emergence of many market players and the availability of abundant opportunities has made the Asia-Pacific the fastest growing region worldwide. The increasing prevalence of eye-disorders, increased healthcare spending and recognition of opportunities by international market players are driving robust growth for the region. According to the WHO, 90% of total visually impaired people live in developing countries in the Asia Pacific region. Countries such as India and China lead market growth and have a vast patient population which is creating a high demand for effective treatment options due to their rapidly growing economies. These economies are driving the demand for improved healthcare services and attracting international players for improvement of healthcare services.

Get Discount on Report - https://www.marketresearchfuture.com/check-discount/5736

Global Age-related Macular Degeneration (AMD) Market – Segmentation

The global age-related macular degeneration is segmented based on type, stages, age group, diagnosis & treatment, route of administration, end-user and region. By type, the market is segmented into wet age-related macular degeneration (Wet AMD) and dry age-related macular degeneration (Dry AMD). Wet AMD accounts for more than 50% of the total market and is expected to grow at the highest CAGR of 7.6% during the forecast period. Wet AMD owes its rapid growth and market leading position to the fact that it is a key cause of 90% acute blindness and the rapidly growing geriatric population.

By stages, the market is segmented into early-stage age-related macular degeneration, intermediate age-related macular degeneration, late-stage age-related macular degeneration. The intermediate stage of AMD is one of the most common forms of AMD and as such holds the largest share of the market and is expected to grow with the fastest CAGR during the assessment period.

By age group, the market is segmented into above 75 years, above 60 years, and above 40 years. Of these, the above 75 segment is poised to grow at the fastest CAGR of 7.5% and presently holds the most significant market share. This is primarily due to the highly common nature of this disease among this age group.

By diagnosis & treatment, the market is segmented into treatment, and diagnosis, with the treatment segment accounting for the largest market share and highest CAGR. Novel treatment methods drive the growth for this segment due to the high demand for treatment of wet AMD.

By route of administration, the market is segmented into intravitreal route of administration and intravenous route administration. The intravitreal route of administration is most popular and holds the largest share of the market and is expected to grow at a CAGR of 7.7% during the review period.

By end-user, the market is segmented into hospital & clinics, diagnostic centers, and academic research institutes. Due to the increasing number of patients seeking treatment, hospitals and clinics hold just over half the market share. This segment is expected to proliferate as the geriatric population increases and is set to witness the fastest CAGR of 7.6%.

Browse Complete TOC Here https://www.marketresearchfuture.com/reports/age-related-macular-degeneration-market-5736

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.